Zai Lab reports Q2 EPS (4c), consensus (42c)

Reports Q2 revenue $110.0M, consensus $125.02M. “Zai Lab (ZLAB) is entering a pivotal period – defined by innovation, scale and strong execution,” said CEO Samantha Du. “We are making meaningful progress throughout our business – expanding patient impact, accelerating global innovation, and operating with financial discipline. Updated ASCO data for ZL-1310 (DLL3 ADC) reaffirm its best-in-class potential in second-line SCLC, and we are moving swiftly into pivotal development while exploring opportunities in first-line SCLC and other neuroendocrine carcinomas. We were also encouraged by positive data for bemarituzumab in first-line gastric cancer and by emerging preclinical results for our IL-13/IL-31 bispecific antibody in atopic dermatitis, reinforcing both our near-term commercial opportunities and the potential of our global pipeline, respectively. With multiple launches ahead, a robust pipeline, and profitability within reach, Zai Lab is executing on its vision to become a leading global biopharma company.”